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Edited by Robert BaroukiAbstract Transforming growth factor-b (TGFb1) is a proan-
giogenic factor both, in vitro and in vivo, that is mainly involved
in the later phases of angiogenesis. In an attempt to identify
genes that participate in this eﬀect, we found that TGFb1 down-
regulates expression of adenylate cyclase VI. In addition, cAMP
analogs (8-Bromo-cAMP) and forskolin (an adenylate cyclase
activator) also reduced TGFb1-induced in vitro angiogenesis in
mouse endothelial cell lines and in primary cultures of human
umbilical vein endothelial cells on collagen gels. Induction of Ets-
1 and plasminogen activator inhibitor-1 (PAI-1) by TGFb1 was
blocked by these cAMP agonists and activators, in the absence
of eﬀects on endothelial cell viability. Moreover, the signal
transduction pathways stimulated by TGFb1 were unaﬀected.
Thus, Smad2 was normally phosphorylated and translocated to
the nucleus in the presence of forskolin. In contrast, transfection
studies using the PAI-1-promoter indicated that these cAMP
analogues inhibit transcriptional stimulation by TGFb1. Elec-
trophoretic mobility shift assay showed that Smad2/3 were
bound normally to a TGFb1-response region in the presence of
the cAMP analogs. In all, these data suggest that the cAMP
pathway inhibits the transcriptional activity of Smads, that could
be responsible for the block of the TGFb1-induced in vitro
angiogenesis caused by this second messenger.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Angiogenesis or the formation of new blood vessels from
pre-existing vasculature occurs in normal situations such as
embryonic development, wound healing and during the female
reproductive cycle. However, activated blood vessel growth is
also found in many diseases, such as tumor progression, dia-
betic retinopathy or arthritis [1,2]. In the last few years, several
studies have led to the discovery of inducers and inhibitors of
angiogenesis [3–5]. Among the inducers there are factors such
as vascular endothelial growth factor (VEGF), FGF-1 and 2
that induce angiogenesis in vivo and in vitro. In contrast, other
factors such as transforming growth factor-b (TGFb) induce* Corresponding author. Fax: +34-93-4024268.
E-mail address: fvinals@ub.edu (F. Vi~nals).
0014-5793/$22.00  2004 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2004.05.058angiogenesis in vivo and in vitro but inhibit endothelial cell
proliferation in vitro [3–5].
TGFb1 is a 25-kDa peptide belonging to a family of multi-
functional cytokines that control the development and ho-
meostasis of most tissues by regulating diverse cellular
functions, such as proliferation and diﬀerentiation [6–8]. The
receptors for this family are basically two transmembrane ser-
ine/threonine kinases, termed receptor type I and type II. The
binding of the ligand causes the heterodimerization of receptors
I and II followed by the activation by phosphorylation of re-
ceptor I. This receptor then phosphorylates and activates the
Smad family of proteins, which transduce the signal to the
nucleus [6,7,9,10]. The role of TGFb in angiogenesis was ﬁrst
shown by new capillary formation after injection of the factor
in mice [11,12] and when applied to chicken chorioallantoic
membrane (CAM) [13]. Moreover, TGFb1 and TGFb2 are
expressed during the development of angiogenically active tis-
sues [14,15]. This proangiogenic activity of TGFb has been
conﬁrmed by experiments using knock-out mice. The knock-
out of TGFb1, the type II receptor and the type I receptor
activin receptor-like kinase 1 (ALK1) are lethal at 10.5 days of
gestation due to defective vasculogenesis (the initial formation
of the primitive vasculature in the embryo), along with defec-
tive endothelial cell diﬀerentiation and inadequate capillary
tube formation [16]. Morevoer, Smad5 knock-out mice also die
due to defects in vasculogenesis and angiogenesis [17,18]. Fi-
nally, mutations in the human ALK1 gene and in the endoglin
gene, a TGFb1-binding protein which presents TGFb1 to the
type I and II receptors, all cause hereditary hemorrhagic tel-
angiectasia, a disease characterized by vascular malformations
[19,20]. Knock-out mice for endoglin also show a defective
angiogenesis and die at embryonic day 11.5 [21]. In vitro, TGFb
inhibits endothelial cell proliferation in two-dimensional cul-
tures [22–25], but induces tube formation when endothelial cells
are cultured inside three-dimensional collagen gels [26–28].
Finally, TGFb1 promotes the in vitro diﬀerentiation of em-
bryonic stem cells to the endothelium as well as the formation
of cord-like structures [29]. The signaling mechanisms impli-
cated in the pro-angiogenic eﬀect of TGFb are now beginning
to be resolved. Thus, it seems clear that at the start of angio-
genesis, TGFb works through the Alk1 receptor type I and
Smad1 phosphorylation, which induces endothelial cells to
proliferate and degrade the extracellular matrix, while in the
last phase of the angiogenesis TGFb signals through the Alk5
receptor and Smad2/3, blocking proliferation and enhancing
extracellular matrix deposition [30]. It has also been shown thatblished by Elsevier B.V. All rights reserved.
106 B. del Valle-Perez et al. / FEBS Letters 569 (2004) 105–111during the last phase TGFb can indirectly stimulate the PI3K/
Akt and the p42/p44 MAPK pathways, which is essential for
cell survival and formation of capillary-like structures [31].
However, although some of the signaling mechanisms have
been identiﬁed, the molecules that participate in the proangi-
ogenic action of TGFb are largely unknown. Using a mouse
vascular endothelial cell model (1G11 cell line), which rapidly
forms capillary-like structures in collagen and responds to
TGFb1, we examined the action of this angiogenic cytokine.
We found a negative eﬀect of cAMP on the proangiogenic ac-
tion of TGFb1, and that one of the genes down-regulated by
TGFb1 is adenylate cyclase VI.Fig. 2. cAMP blocks TGFb1-induced in vitro angiogenesis in 1G11 and HUV
collagen gels and TGFb1 (25 ng/ml) alone or in the presence of 1 mM 8-B
microscopy.
Fig. 1. TGFb1 blocks adenylate cyclase VI mRNA and protein.
(A) 1G11 cells immersed in collagen gels were cultured for 4 h in the
presence of DMEM alone (Basal) or 25 ng of TGFb1/ml (TGFb1).
Cells were lysed and total RNA was isolated. Gels were loaded with 25
lg of RNA and after blotting, adenylate cyclase VI (ACVI) and
GAPDH were detected by hybridization using speciﬁc probes. A rep-
resentative autoradiogram is shown. (B) 1G11 endothelial cells im-
mersed in collagen gels were cultured for 48 h in the presence of
DMEM alone (Basal) or 25 ng of TGFb1/ml. Cells were lysed and
adenylate cyclase VI was detected by immunoblotting with a speciﬁc
antibody. b-Actin is shown as a loading control. A representative
Western blot of three diﬀerent experiments is shown.2. Materials and methods
2.1. Materials
Human recombinant TGFb1 was obtained from R&D Systems, and
forskolin and 8-Bromo-cAMP were from Sigma, 5,6-dichloro-1-b-D-
ribofuranosylbenzimidazole (DRB) was from Calbiochem. Cell culture
media, FBS, glutamine and antibiotics were obtained from Gibco-
BRL. The other reagents were of analytical or molecular biology grade
and purchased from Sigma or Roche.
2.2. Cell culture and transfections
Murine lung capillary endothelial cells (cell line 1G11) were obtained
from Alberto Mantovani and Annunciata Vecchi (Instituto Ricerche
Farmacologiche Mario Negri, Milan, Italy) [32]. They were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 20% FBS;
50 U of penicillin, 50 lg of streptomycin sulfate, 150 lg of endothelial
cell growth supplement (Becton–Dickinson) and 100 lg of heparin
(Sigma)/ml; 1% non-essential amino acids; and 2 mM sodium pyru-
vate. When indicated, 8-Br-cAMP or forskolin were added 10 min
before the addition of TGFb1.
1G11 cells were transiently transfected with a plasmid containing the
TGFb-responsive region of the plasminogen activator inhibitor-1
(PAI-1) promoter (3TP-lux) [33] and a b-galactosidase vector using
Lipofectamine 2000 (Invitrogen). Luciferase assays were carried out
using the Luciferase Assay System (Promega) 48 h after transfection
and 16 h after treatment with 5 ng of TGFb1/ml. b-Galactosidase
activity was measured using a Luminescent b-galactosidase Detection
Kit II (Clontech).
Human umbilical vein endothelial cells (HUVEC) were obtained as
previously described [34] and were cultivated in M199 (Gibco) sup-
plemented with 20% FCS, 100 lg/ml heparin and 150 lg/ml of endo-
thelial cell growth supplement (Becton–Dickinson).
2.3. Tubulogenesis assays and cell survival
To induce capillary tube formation, 1G11 cells grown to conﬂuence
were trypsinized and resuspended in 2 DMEM. Cells were added to a
type I collagen solution (Becton–Dickinson; 4 mg/ml) to achieve a cell
concentration of 3 106 cells/ml and a ﬁnal collagen concentration of
2 mg/ml. Sixty microliters of this preparation was placed in 24-well
plates and incubated for 45 min at 37 C in a humidiﬁed incubator to
allow polymerization and DMEM alone or DMEM containing 25 ng
of TGFb1/ml was added where indicated. When indicated, 1 mM 8-Br-
cAMP was added 10 min before TGFb1. Protein extracts were ob-
tained from the gels as described [31].
For HUVEC, 2 105 cells were seed in triplicate into a 24-well plate
coated with 300 ll of rat tail collagen type I (1.2 mg/ml) in M199 and
10% FCS and allowed to attach for at least 2 h. Following this, cells
were overlayed with an additional 300 ll of collagen. Once the collagen
had polymerized, cells were fed with M199 medium, 10% FCS, 100 lg/
ml heparin, 150 lg/ml of endothelial cell growth supplement, 25 ng/ml
of TGFb1 in the absence or presence of 1 mM 8-Br-cAMP. FollowingEC cultures in type I collagen gels. 1G11 or HUVEC were cultured on
r-cAMP were added for 24 h. Gels were examined by phase-contrast
Fig. 3. cAMP prevents TGFb1 induction of Ets-1 and PAI-1. (A) 1G11
endothelial cells immersed in collagen gels were cultured for 48 h in the
presence of DMEM alone (Basal) or 25 ng of TGFb1/ml either alone
or with 1 mM 8-Br-cAMP. Cells were lysed and Ets-1 was detected by
immunoblotting with a speciﬁc antibody. ERK2 is shown as a loading
control. Lines 1 and 2, 3 and 4, and 5 and 6 correspond to duplicates.
A representative Western blot of three diﬀerent experiments is shown.
(B) Depleted 1G11 endothelial cells cultured on plastic plates were
stimulated with 25 ng of TGFb1/ml alone or in the presence of 25 lM
forskolin (F) or 1 mM 8-Br-cAMP (8Br) for 2 or 6 h or not stimulated
(B). Cells were lysed and total RNA was isolated and analyzed by
Northern blot. After blotting, PAI-1 or GAPDH (as a loading control)
were detected by hybridization using a speciﬁc probe. A representative
autoradiography is shown. (C) Depleted 1G11 endothelial cells cul-
tured on plastic plates were incubated with diﬀerent treatments. 1,
DMEM alone for 6 h; 2, 25 ng of TGFb1/ml for 6 h; 3, 25 ng of
TGFb1/ml for 6 h in the presence of 5 lg/ml of actinomycin D; 4, 25 ng
of TGFb1/ml for 6 h in the presence of 5 lg/ml of actinomycin D and 1
mM 8-Br-cAMP; 5, 25 ng of TGFb1/ml for 3 h, and addition of 5 lg/
ml of actinomycin D for additional 3 h; 6, 25 ng of TGFb1/ml for 3 h,
and addition of 5 lg/ml of actinomycin D and 1 mM 8-Br-cAMP for
additional 3 h; 7, 25 ng of TGFb1/ml for 6 h in the presence of 100 lM
DRB; 8, 25 ng of TGFb1/ml for 6 h in the presence of 100 lM DRB
and 1 mM 8-Br-cAMP; 9, 25 ng of TGFb1/ml for 3 h, and addition of
100 lM DRB for additional 3 h and 10, 25 ng of TGFb1/ml for 3 h,
and addition of 100 lM DRB and 1 mM 8-Br-cAMP for additional 3
h. After these treatments, RNA was obtained, and PAI-1 or GAPDH
were detected by hybridization using a speciﬁc probe. A representative
autoradiography of two independent experiments is shown.
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captured on a Leica inverted phase-contrast microscope DMIRBE
equipped with digital capture software.
To measure the viability of 1G11 cells after 24 h in collagen gels,
propidium iodide (1 lg/ml; Sigma) was added and incubated for 10
min at 37 C. Phase-contrast or immunoﬂuorescence images were
obtained using an immunoﬂuorescence microscope.
2.4. Suppression substractive hybridization PCR-based technique
To identify genes expressed diﬀerentially by the presence of TGFb1,
1G11 cells immersed in type I collagen gels were incubated for 4 h in
the absence or presence of 25 ng of TGFb1/ml. Cells were lysed and
poly(A)þ was isolated. The subtracted library was obtained using a kit
of Clontech based on the suppression subtractive hybridization PCR-
based technique [35]. The cDNAs obtained were subcloned in a TOPO
cloning vector (Invitrogen) and sequenced.
2.5. Western blot analysis
Cells were washed twice in cold phosphate-buﬀered saline (PBS) and
lysed in Triton X-100 lysis buﬀer (50 mM Tris–HCl, pH 7.5, 100 mM
NaCl, 50 mM NaF, 5 mM EDTA, 40 mM b-glycerophosphate, 200
lM sodium orthovanadate, 100 lM phenylmethylsulfonyl ﬂuoride, 1
lM pepstatin A, 1 lg/ml of leupeptin, 4 lg/ml of aprotinin and 1%
Triton X-100) for 15 min at 4 C. Western blots were performed as
described [36]. The blots were incubated with polyclonal anti-adenylate
cyclase V/VI antibody (Santa Cruz), polyclonal anti-Ets-1 antibody
(Santa Cruz), polyclonal anti-PARP antibody (Cell Signaling), poly-
clonal anti-phospho-Smad2 antibody (Upstate Biotechnology), poly-
clonal anti-phospho-CREB (Cell Signaling), monoclonal anti-b-actin
antibody (Sigma) or polyclonal anti-ERK2 [37] in blocking solution
overnight at 4 C.
2.6. Northern blot
Total RNA from cells was extracted using the phenol/chloroform
method [38], and Northern blot with 20 lg of RNA was performed as
described [36]. Blots were hybridized to the mouse PAI-1 cDNA (a
generous gift from Dr. Pura Mu~noz-Canoves) or rat GAPDH cDNA
labelled with [a-32P]dCTP (Amersham Pharmacia).
2.7. Immunoﬂuorescence studies
Cells were cultured on glass coverslips for 24 h, depleted of growth
factors and treated with the diﬀerent factors. Cells were rinsed three
times with PBS and ﬁxed in 3% paraformaldehyde for 30 min. After
four washes with PBS, they were permeabilized with PBS–0.2% Triton
X-100 for 5 min, rinsed four times with PBS and blocked for 30 min at
room temperature in PBS containing 2% bovine serum albumin.
Coverslips were incubated with mouse monoclonal anti-Smad2/3 an-
tibody (BD Transduction Laboratories) in blocking solution for 1 h at
room temperature, followed by Texas red anti-mouse (Molecular
Probes) for 1 h at room temperature. Coverslips were mounted using
Mowiol (Calbiochem) and immunoﬂuorescence was visualized with a
Nikon Eclipse E800 microscope.
2.8. Electrophoretic mobility shift assay
Preparation of the nuclear extract was performed as described by
Ausubel et al. [39]. The DNA probe that responded to TGFb1 was
that described by Dennler et al. [40], with the following sequence:
50-TCGAGAGCCAGACAAG GAGCCAGACAAGGAGCCAGA-
CAC-30. The oligonucleotides were 32P-end-labeled using T4-polynu-
cleotide kinase (MBI-Fermentas). The gel mobility shift assays were
performed in a 15-ll reaction volume, containing 1 lg of double-
stranded poly(dI–dC), 25 000 cmp of labeled DNA probe, 5 lg of
protein nuclear extract, 10 mM HEPES, pH 7.9, 10% glycerol, 50 mM
KCl, 0.1 mM EDTA and 0.25 mM dithiothreitol. The mixture (with-
out the labeled DNA) was incubated for 15 min at room temperature.
After the addition of the labeled DNA, the reaction mixture was in-
cubated for another 15 min at room temperature, immediately loaded
on a 5% polyacrylamide gel and run in 0:5 TBE buﬀer (45 mM Tris,
45 mM boric acid and 1 mM EDTA, pH 8) for 3–4 h. The gels were
dried and autoradiographed.
Supershifts experiments were performed by incubating nuclear ex-
tracts, poly(dI–dC) and end-labeled probe as detailed above followed
by incubation for 15 min at 37 C in the presence of 0.25 lg of Smad2/3
antibody (BD Transduction Laboratories) or Smad4 (a generous giftfrom Dr. Joan Massague). The samples were loaded on a 5% poly-
acrylamide gel, dried and autoradiographed.3. Results
To identify genes involved in the pro-angiogenic eﬀect of
TGFb1, we generated a subtracted cDNA library from 1G11
cells, immersed on collagen type I gels and treated for 4 h with
TGFb1, using the suppression subtractive hybridization PCR-
based technique [35]. Among the genes repressed by TGFb1,
we have found the adenylate cyclase VI cDNA [41,42].
108 B. del Valle-Perez et al. / FEBS Letters 569 (2004) 105–111Northern and Western blot experiments conﬁrmed that
adenylate cyclase VI mRNA and protein were repressed by
TGFb1 (Fig. 1). Adenylate cyclases are responsible for the
production of cAMP in response to extracellular signals. Gi-
ven the observed negative eﬀect of TGFb1 on adenylate cy-
clase VI, we evaluated the eﬀect of cAMP on an in vitro model
of angiogenesis stimulated by TGFb1. 1G11 cells cultured on
collagen type I gels formed tubular structures after 24 h in-
cubation with TGFb1 (Fig. 2). In contrast, pre-incubation in
the presence of 8-Bromo-cAMP, a cell permeable analog of
cAMP more resistant to phosphodiesterases, blocked the pro-
angiogenic eﬀect. We obtained the same results using primary
cultures of HUVEC (Fig. 2): TGFb1 caused the reorganization
of the cells on collagen type I gels. In contrast, incubation in
the presence of 8-Br-cAMP blocked the reorganization.
To conﬁrm this inhibitory eﬀect of cAMP on TGFb1-in-
duced in vitro angiogenesis, we studied the induction of a
typical angiogenic marker, transcription factor Ets-1
[28,31,43]. TGFb1 stimulated Ets-1 expression, but this in-
duction was completely abolished by 8-Br-cAMP (Fig. 3A). A
known TGFb immediate responsive gene at the transcriptional
level is PAI-1 [44]. To evaluate whether the blocking eﬀect of 8-
Br-cAMP on TGFb1 actions was exerted at the transcriptional
level, we performed Northern blot experiments using the
cDNA for PAI-1 as a probe. Increasing cAMP levels by in-Fig. 4. cAMP does not aﬀect 1G11 cells viability. (A) 1G11 were cultured on
presence of 1 mM 8-Br-cAMP were added for 24 h. After propidium iodide
noﬂuorescence microscopy. (B) Proliferative 1G11 endothelial cells (2D) or
presence of DMEM alone (Basal) or 25 ng of TGFb1/ml either alone or w
immunoblotting with a speciﬁc antibody. b-Actin is shown as a loading con
1G11 cells, three of Basal, three of TGFb1 and two of TGFb1+ 8-Br-cAMPcubating cells either with forskolin or with 8-Br-cAMP in-
hibited the stimulation of PAI-1 mRNA by TGFb1 in 1G11
cells (Fig. 3B). In order to discart an eﬀect of cAMP on mRNA
stability, we incubated 1G11 cells in the presence of TGFb1 for
6 h. At the same time or 3 h later, 5 lg/ml of actinomycin D or
100 lM DRB were added to the samples to stop RNA syn-
thesis (without change of the culture medium) for additional 3
h in the absence or presence of 1 mM 8-Br-cAMP. RNA was
obtained and PAI-1 or GAPDH were detected by Northern
blot. As is observed in Fig. 3C, presence of 8-Br-cAMP did not
modify mRNA PAI-1 decay rate. Thus, cAMP not only af-
fected the morphological reorganization of endothelial cells to
form tubular structures, but TGFb1 early induced genes were
also blocked.
To identify the mechanisms involved in the eﬀect of cAMP
on TGFb1-stimulated in vitro angiogenesis and gene expres-
sion, we ﬁrst evaluated a possible eﬀect of cAMP on endo-
thelial cell viability. 1G11 cells cultured on collagen gels were
incubated in the presence of 1 mM 8-Br-cAMP and 25 ng of
TGFb1/ml for 24 h. Cell viability was evaluated by propidium
iodide staining (labeling the nuclei of dead cells with con-
densed chromatin). As shown in Fig. 4A, no diﬀerences were
observed between cultures in the absence or presence of 8-Br-
cAMP. We also analyzed PARP cleavage as a measure of
apoptosis. No signiﬁcant diﬀerences were observed betweencollagen gels and DMEM (Basal), TGFb1 (25 ng/ml) alone or in the
addition for 10 min, gels were examined by phase-contrast or immu-
immersed in collagen gels (24 h in 3D) were cultured for 24 h in the
ith 1 mM 8-Br-cAMP. Cells were lysed, and PARP was detected by
trol. Results obtained from two independent samples of proliferative
are shown.
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of 1 mM 8-Br-cAMP (Fig. 4B). When cells were maintained
for 4 days with the same factors, 8-Br-cAMP increased ap-
optosis (data not shown).
Next, we analyzed the eﬀect of cAMP on the TGFb1 sig-
nalling pathways. 1G11 cells were pre-incubated in the pres-
ence of forskolin followed by TGFb1 addition for 1, 2, 4 or
8 h. We did not detect any diﬀerence in Smad2 phosphoryla-
tion by TGFb1 in the absence or presence of forskolin, in
conditions where CREB was phosphorylated by high levels of
cAMP (Fig. 5A). Smad2/3 are translocated to the nucleus after
their phosphorylation by the TGFb receptor type I. Thus, one
possibility was that cAMP modiﬁed the translocation of
Smad2/3 in response to TGFb. To test this hypothesis we
performed immunoﬂuorescence studies using antibodies
against total Smad2/3 (Fig. 5B). In the basal state, Smad2/3
was mainly located in the cytoplasm. In contrast, incubation
with TGFb1 for 1 h caused the translocation of Smad2/3 to the
nucleus, which was not aﬀected by incubation with either
forskolin or 8-Br-cAMP.
We also evaluated a possible eﬀect of cAMP on the tran-
scriptional activity of Smads. We transfected 1G11 cells withFig. 5. cAMP does not aﬀect TGFb1 signaling. (A) Depleted 1G11
cells were pre-incubated in the absence ()F) or presence (+F) of 25 lM
forskolin for 10 min. After that, 25 ng of TGFb1/ml was added for the
indicated periods of time. Cells were lysed and phosphoSmad2,
phosphoCREB or b-actin were immunodetected by Western blot. A
representative autoradiogram of three independent experiments is
shown. (B) Depleted 1G11 cells were pre-incubated in the absence or
presence of 1 mM 8-Br-cAMP or 25 lM forskolin for 10 min. After
this time, cells were incubated for 1 h in the absence (Basal) or
the presence of 25 ng of TGFb1/ml. Cells were ﬁxed and Smad2/3
immunolocalized.a plasmid containing the TGFb-responsive region of the PAI-
1 promoter [33]. TGFb1 caused a threefold increase in the
activity of the promoter in these cells, whereas incubation in
the presence of 8-Br-cAMP abolished this induction (Fig.
6A). This eﬀect on the promoter activity could be due to a
lack of binding of the transcriptional activators Smad2/3–
Smad4 to the speciﬁc zones of the promoter. To test this
possibility, we performed electrophoretic mobility shift assays
(EMSA) using nuclear extracts from 1G11 cells non-treated
or treated for 1 h with TGFb1 or with this factor in the
presence of forskolin, using the TGFb-responsive region of
the PAI-1 promoter as a probe [40]. Incubation with TGFb1
caused a shift in the mobility of the probe due to the presence
of Smad2/3 present in the nuclear extracts, as conﬁrmed by
super-shift assays (Fig. 6B). However, the presence of for-
skolin in the incubation medium did not alter the pattern ofFig. 6. cAMP blocks TGFb1-induced promoter transcription but does
not aﬀect Smad2/3 binding to DNA. (A) 1G11 cells were transiently
transfected with 3TP-lux reporter and b-galactosidase transfection
control, incubated for 24 h in complete medium, rinsed with PBS and
incubated for additional 16 h in the presence of 1 mM 8-Br-cAMP in
the absence of growth factors (Basal) or the presence of 5 ng of
TGFb1/ml. Cells were harvested, and luciferase and b-galactosidase
activities were measured. The results are means S.E.M. of three
diﬀerent experiments. (B) A TGFb-responsive region of the PAI-1
promoter was incubated with 5 lg of nuclear extracts from 1G11 cells
treated for 1 h in the absence (Basal) or the presence of 25 ng of
TGFb1/ml alone or in the presence of 25 lM forskolin (TGFb1+F).
An antibody against Smad4 or Smad2/3 was added or not and samples
were analyzed on a 5% polyacrylamide gel. Arrows indicating the
complexes Smad4, Smad2/3–Smad4 and the supershift caused by the
antibodies are included.
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taining complexes.4. Discussion
Agents that increase cAMP levels, such as prostaglandins,
b-adrenergic agonists or phosphodiesterase inhibitors, all
decrease endothelial cell barrier permeability by promoting
attachment to the basal membrane [45,46]. Moreover, in-
creased cAMP levels block the pro-angiogenic eﬀects of sev-
eral factors, such as migration, proliferation and in vitro
angiogenesis of HUVEC induced by VEGF and bFGF
[47,48], in vitro angiogenesis stimulated by collagen I of
dermal microvascular endothelial cells [49], and in vivo an-
giogenesis stimulated by bFGF in the CAM assay [50,51].
Here, we show that this inhibitory eﬀect of cAMP is also
observed for a distinct angiogenic factor, TGFb1. In contrast
to VEGF or bFGF, which stimulate the ﬁrst phases of an-
giogenesis and induce matrix degradation, proliferation and
migration of endothelial cells, TGFb1 participates in the later
phases of angiogenesis, when endothelial cells become more
quiescent [3,30,52]. Thus, TGFb1 blocks endothelial cell
proliferation, increases basement membrane deposition and
causes morphological organization to form the capillaries.
The capacity of cAMP to block angiogenesis stimulated by
both types of factors implies that this second messenger af-
fects a common mechanism for angiogenesis, such as the re-
organization and migration of the endothelial cells.
Alternatively cAMP may induce apoptosis [51]. However in
our model, apoptosis only occurs after much longer incuba-
tion times, implicating other mechanisms involved in the anti-
angiogenic response.
Our results also show that cAMP aﬀects the ability of
TGFb1 to stimulate gene transcription. Thus, PAI-1 mRNA
and promoter activity are decreased in conditions where
TGFb-induced Smad2/3 phosphorylation, translocation to the
nucleus and binding to DNA were not altered by cAMP ac-
tivation. cAMP also blocks TGFb1-induced transcription for
other genes in endothelial cells, such as c-sis [53], but the
mechanisms that cause this block of TGFb1-dependent tran-
scription remain unknown. Recently it has been described that
the inhibitory eﬀect of cAMP on TGFb-induced transcription
in HaCaT keratinocytes is mediated by diminishing the asso-
ciation of Smad3 with transcriptional coactivators CBP and
p300 [54]. cAMP may also induce the recruitment of a re-
pressor of the Smads complex that blocks transcription, sim-
ilarly to the recruitment of ATF3 for Id1 repression by TGFb
in epithelial cells [55]. Finally, a third possibility is the induc-
tion of the phosphorylation of Smads by cAMP, which would
reduce its transcriptional activity. This negative regulation of
the transcriptional activity of Smads by phosphorylation has
already been described for Ca2þ/calmodulin-dependent protein
kinase II and for PKC [8].
Our results also indicate that one of the eﬀects of TGFb1 on
endothelial cells is to decrease the levels of adenylate cyclase
VI. This enzyme is highly expressed in endothelial cells [56] and
its negative regulation is responsible for the down-regulation
of the levels of cAMP by Ca2þ [46]. Other pro-angiogenic
stimuli decrease cAMP levels in a similar way. Thus, activation
of integrins a1b1 and a2b1 by collagen I decreases cAMPlevels and PKA activity in human dermal microvascular en-
dothelial cells [49], and activation of a5b1 by vitronectin
suppresses PKA activity in HUVEC [50]. The mechanisms
responsible for these eﬀects are unknown, but the TGFb-in-
duced decrease in the levels of adenylate cyclase VI may con-
tribute to the suppression of cAMP during angiogenesis.
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